Needham analyst Michael Matson (NYSE:MATX) reiterated a Buy rating on Axonics Modulation Technologies (NASDAQ:AXNX) on Monday, setting a price target of $78, which is approximately 16.59% above the present share price of $66.9.
Matson expects Axonics Modulation Technologies to post earnings per share (EPS) of -$0.57 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Axonics Modulation Technologies, with an average price target of $71.25.
The analysts price targets range from a high of $78 to a low of $62.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $34.37 million and a net profit of -$17.2 million. The company's market cap is $3.07 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.6% and a 71.86% success rate.
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.